Rhumbline Advisers Raises Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Rhumbline Advisers increased its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 5.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 108,228 shares of the specialty pharmaceutical company’s stock after buying an additional 5,920 shares during the period. Rhumbline Advisers owned about 0.34% of Collegium Pharmaceutical worth $3,101,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Victory Capital Management Inc. increased its holdings in Collegium Pharmaceutical by 43.6% during the third quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock valued at $27,461,000 after buying an additional 215,874 shares during the period. Emerald Advisers LLC boosted its position in Collegium Pharmaceutical by 27.2% during the 3rd quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock valued at $31,967,000 after acquiring an additional 177,129 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Collegium Pharmaceutical by 173.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after acquiring an additional 175,892 shares during the period. Emerald Mutual Fund Advisers Trust raised its position in shares of Collegium Pharmaceutical by 24.9% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 662,291 shares of the specialty pharmaceutical company’s stock worth $25,591,000 after acquiring an additional 131,835 shares in the last quarter. Finally, Empowered Funds LLC purchased a new stake in shares of Collegium Pharmaceutical during the 3rd quarter worth $4,693,000.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the business’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the sale, the executive vice president now owns 119,184 shares in the company, valued at approximately $3,937,839.36. The trade was a 18.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.98% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

COLL has been the topic of several analyst reports. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research note on Friday, January 10th. Piper Sandler cut their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 4th. Finally, HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $43.60.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $29.05 on Friday. Collegium Pharmaceutical, Inc. has a fifty-two week low of $27.84 and a fifty-two week high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The company has a market cap of $936.86 million, a PE ratio of 12.52 and a beta of 0.82. The business has a 50-day simple moving average of $30.82 and a two-hundred day simple moving average of $33.47.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.09. The company had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. As a group, equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.